SIBN vs. EMBC, TMCI, ATRI, IRMD, OFIX, SILK, KIDS, SRDX, OSUR, and NVRO
Should you be buying SI-BONE stock or one of its competitors? The main competitors of SI-BONE include Embecta (EMBC), Treace Medical Concepts (TMCI), Atrion (ATRI), Iradimed (IRMD), Orthofix Medical (OFIX), Silk Road Medical (SILK), OrthoPediatrics (KIDS), Surmodics (SRDX), OraSure Technologies (OSUR), and Nevro (NVRO). These companies are all part of the "surgical & medical instruments" industry.
SI-BONE (NASDAQ:SIBN) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.
98.1% of SI-BONE shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 5.4% of SI-BONE shares are owned by company insiders. Comparatively, 0.3% of Embecta shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Embecta has higher revenue and earnings than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.
SI-BONE received 160 more outperform votes than Embecta when rated by MarketBeat users. Likewise, 67.23% of users gave SI-BONE an outperform vote while only 0.00% of users gave Embecta an outperform vote.
In the previous week, SI-BONE had 21 more articles in the media than Embecta. MarketBeat recorded 26 mentions for SI-BONE and 5 mentions for Embecta. SI-BONE's average media sentiment score of 0.33 beat Embecta's score of 0.04 indicating that SI-BONE is being referred to more favorably in the media.
Embecta has a net margin of 4.93% compared to SI-BONE's net margin of -31.20%. Embecta's return on equity of -18.66% beat SI-BONE's return on equity.
SI-BONE currently has a consensus target price of $27.29, suggesting a potential upside of 74.57%. Embecta has a consensus target price of $16.00, suggesting a potential upside of 12.44%. Given SI-BONE's stronger consensus rating and higher probable upside, analysts plainly believe SI-BONE is more favorable than Embecta.
SI-BONE has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500. Comparatively, Embecta has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
Summary
SI-BONE beats Embecta on 11 of the 18 factors compared between the two stocks.
Get SI-BONE News Delivered to You Automatically
Sign up to receive the latest news and ratings for SIBN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SIBN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
